Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer.

@article{Funai2010FeasibilitySO,
  title={Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer.},
  author={Kazuhito Funai and Kazuya Takamochi and Toru Itaya and Takahiro Mochizuki and Toshihiko Nakamura and Futoru Toyoda and Kim Yong-Il and Kazuyoshi Sasaki and Shigeru Momiki and Tsuyoshi Takahashi and Hiroshi Neyatani and Kazuya Suzuki},
  journal={Lung cancer},
  year={2010},
  volume={68 1},
  pages={78-83}
}
INTRODUCTION Recent clinical trials have shown significant survival benefits from postoperative adjuvant chemotherapy for resected non-small-cell lung cancer (NSCLC). However, due to the comparatively low compliance in recent clinical trials, this study investigated the feasibility of adjuvant chemotherapy with gemcitabine plus split-dose cisplatin for completely resected NSCLC. METHODS Gemcitabine at a dose of 1000 mg m(-2) and cisplatin at 40 mg m(-2) were given intravenously on days 1 and… CONTINUE READING
3 Extracted Citations
9 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-9 of 9 references

Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of 5 randomized trials including 4584 patients

  • JP Pignon, H Tribodet, GV Scagliotti, JY Douillard, FA Shepherd, RJ Stephens
  • J Clin Oncol 2006;24:366S [abstr
  • 2006

Similar Papers

Loading similar papers…